Vnitr Lek 2015, 61(10):900-904

Acromegaly: current view

Michal Kršek
III. interní klinika - klinika endokrinologie a metabolizmu 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Acromegaly is a rare disorder caused by autonomous oversecretion of growth hormone mostly by pituitary adenoma. Untreated acromegaly leads to significantly increased morbidity and mortality and impaired quality of life. Early diagnosis and treatment is therefore essential for improvement of patients' prognosis and management of acromegaly should be concentrated in specialized centres. Present article summarizes current view on diagnosis and treatment of acromegaly.

Keywords: acromegaly; diagnosis; presentation; treatment

Received: August 16, 2015; Accepted: September 25, 2015; Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kršek M. Acromegaly: current view. Vnitr Lek. 2015;61(10):900-904.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marie P. On two case of acromegaly: marked hypertrophy of the upper and Loir limbs and the head. Rev Med 1886; 6: 297-333.
    2. Alexander L, Appleton D, Hall R et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12(1): 71-79. Go to original source... Go to PubMed...
    3. Begtsson BA, Eden S, Ernest I et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955-1984. Acta Medica Scand 1988; 223(4): 327-335. Go to original source... Go to PubMed...
    4. Melmed S, Kleinberg D. Anterior Pituitary. In: Kronenberg HM, Melmed S, Polonsky KS et al. Williams textbook of endocrinology. Philadelphia: Saunders Elsevier 200: 155-261. ISBN: 9781416029113.
    5. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988; 67(1): 69-73. Go to original source... Go to PubMed...
    6. Katznelson L, Laws ER Jr, Melmed S et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99(11): 3933-3951. Go to original source... Go to PubMed...
    7. Kan E, Kan EK, Atmaca A et al. Visual field defects in 23 acromegalic patients. Int Ophthalmol 2013; 33(5): 521-525. Go to original source... Go to PubMed...
    8. McLaughlin N, Laws ER, Oyesiku NM et al. Pituitary centers of excellence. Neurosurgery 2012; 71(5): 916-924. Go to original source... Go to PubMed...
    9. Jane jr. JA, Starke RM, Elzoghby MA et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications and predictors of outcome. J Clin Endocrinol Metab 2011; 96(9): 2732-2740. Go to original source... Go to PubMed...
    10. Starke RM, Raper DM, Payne SC et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013; 98(8): 3190-3198. Go to original source... Go to PubMed...
    11. Caron PJ, Bevan JS, Petersenn S et al. Tumor shrinkagewith lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014; 99(4): 1282-1290. Go to original source... Go to PubMed...
    12. Giustina A, Mazziotti G, Torri V et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012; 7(5): e36411. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0036411>. Go to original source... Go to PubMed...
    13. Giustina A, Bonadonna S, Bugari G et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on convenctional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009; 161(2): 331-338. Go to original source... Go to PubMed...
    14. Gadelha MR, Bronstein MD, Brue T et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2(11): 875-84. Go to original source... Go to PubMed...
    15. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295): 1754-1759. Go to original source... Go to PubMed...
    16. Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156(1): 75-82. Go to original source... Go to PubMed...
    17. Neggers SJ, de Herder WW, Feelders RA et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011; 14(3): 253-258. Go to original source... Go to PubMed...
    18. Ježková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly - long-term experience. Clin Endocrinol (Oxf) 2006; 64(5): 588-595. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.